(DSGN) Design Therapeutics - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 659m USD | Total Return: 170% in 12m
Avg Turnover: 9.16M
Qual. Beats: 2
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
Rs Leader
Design Therapeutics Inc (DSGN) is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for genetic disorders caused by nucleotide repeat expansions. The company utilizes its proprietary GeneTAC platform to engineer molecules that target specific DNA sequences to modulate gene expression. Its current pipeline includes candidates for Friedreich Ataxia, Myotonic Dystrophy Type-1, Fuchs Endothelial Corneal Dystrophy, and Huntington’s Disease.
Operating within the biotechnology sector, the company follows a high-risk, high-reward business model typical of clinical-stage firms, where value is primarily driven by the progression of drug candidates through regulatory trial phases. Unlike traditional small molecules that inhibit proteins, GeneTAC molecules are designed to address the underlying genomic cause of disease by either increasing or decreasing the transcription of specific genes.
Investors should review the latest clinical data updates on ValueRay to better understand the companys developmental milestones.
Founded in 2017 and based in Carlsbad, California, Design Therapeutics focuses on monogenic diseases that currently lack effective disease-modifying treatments. The firm’s approach targets the mitochondrial, neurological, and neuromuscular dysfunctions associated with these inherited conditions.
- Clinical trial data for Friedreich Ataxia candidate determines GeneTAC platform viability
- Regulatory approval milestones for Myotonic Dystrophy Type-1 program influence valuation
- Cash runway and R&D expenditure levels dictate future equity financing needs
- Expansion of GeneTAC pipeline into Huntingtons Disease drives long-term growth prospects
- Intellectual property protection for small molecule nucleotide repeat expansion technology
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA -3.41 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.23 > 3% & CFO -54.0m > Net Income -69.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 22.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.4m) vs 12m ago 8.24% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.25%; Δ -0.25% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.94 (Total Current Assets 227.0m - Total Current Liabilities 10.2m) / Total Assets 230.4m |
| B: -1.37 (Retained Earnings -314.6m / Total Assets 230.4m) |
| C: -0.32 (EBIT TTM -74.0m / Avg Total Assets 234.0m) |
| D: 17.60 (Book Value of Equity 218.1m / Total Liabilities 12.4m) |
| Altman-Z'' = 18.08 = AAA |
As of June 12, 2026, the stock is trading at USD 10.53 with a total of 692,327 shares traded.
Over the past week, the price has changed by -2.14%,
over one month by -32.54%,
over three months by +5.19% and
over the past year by +170.00%.
Design Therapeutics has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold DSGN.
- StrongBuy: 0
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21 | 99.4% |
P/S = 29402.82
P/B = 3.0247
Revenue TTM = 0.0 USD
EBIT TTM = -74.0m USD
EBITDA TTM = -73.3m USD
Long Term Debt = 2.20m USD (estimated: total debt 2.73m - short term 536k)
Short Term Debt = 536k USD (from shortTermDebt, last quarter)
Debt = 2.73m USD (from shortLongTermDebtTotal, last quarter) (leases 2.73m already included)
Net Debt = -220.1m USD (calculated: Debt 2.73m - CCE 222.8m)
Enterprise Value = 438.8m USD (658.9m + Debt 2.73m - CCE 222.8m)
Interest Coverage Ratio = unknown (Ebit TTM -74.0m / Interest Expense TTM 0.0)
EV/FCF = -8.11x (Enterprise Value 438.8m / FCF TTM -54.1m)
FCF Yield = -12.33% (FCF TTM -54.1m / Enterprise Value 438.8m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 622k) / Revenue TTM)
Tobins Q-Ratio = 1.90 (Enterprise Value 438.8m / Total Assets 230.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.73m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -58.4m (EBIT -74.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.28 (Total Current Assets 227.0m / Total Current Liabilities 10.2m)
Debt / Equity = 0.01 (Debt 2.73m / totalStockholderEquity, last quarter 218.1m)
Debt / EBITDA = 3.00 (negative EBITDA) (Net Debt -220.1m / EBITDA -73.3m)
Debt / FCF = 4.07 (negative FCF - burning cash) (Net Debt -220.1m / FCF TTM -54.1m)
Total Stockholder Equity = 210.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -29.80% (Net Income -69.7m / Total Assets 230.4m)
RoE = -33.07% (Net Income TTM -69.7m / Total Stockholder Equity 210.8m)
RoCE = -34.72% (EBIT -74.0m / Capital Employed (Equity 210.8m + L.T.Debt 2.20m))
RoIC = -26.46% (negative operating profit) (NOPAT -58.4m / Invested Capital 220.8m)
WACC = 13.56% (E(658.9m)/V(661.7m) * Re(13.62%) + D(2.73m)/V(661.7m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 13.62% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 100.00 | Cagr: 4.08%
[DCF] Fair Price = unknown (Cash Flow -54.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.58 | # QB: 2
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.34 | Chg30d=+3.83% | Revisions=+25% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.36 | Chg30d=+0.94% | Revisions=+43% | Analysts=7
EPS current Year (2026-12-31): EPS=-1.36 | Chg30d=+3.13% | Revisions=+11% | GrowthEPS=-11.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.64 | Chg30d=+4.57% | Revisions=+11% | GrowthEPS=-20.3% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +43%